No Detail Found!

Current trends and availability of injectable therapy in pakistan for management of diabetes mellitus

Author(s)
Muhammad Shahzad Nawaz Department of pharmacy, Punjab University College of Pharmacy, Lahore, Pakistan
Hafiza Shizza Rafique Department of Pharmacy, Quaid-i-Azam University Islamabad, Pakistan
Tooba Malik Department of Public Health, Health Services Academy, Islamabad, Pakistan
Muhammad Umar Wahab Umar Diabetes and Foot Care Centre and Umar Diabetes Foundation, Pakistan
Anwaar Ul Hassan Chughtai Faculty of Medicine and Community Health, University of Oslo, Norway, Pakistan
Muhammad Sarfraz Nawaz Department of Pharmacy, Quaid-i-Azam University Islamabad, Pakistan
Muhammad Daoud Butt Department of Pharmacy, Quaid-i-Azam University Islamabad, Pakistan; School of Pharmaceutical Sciences, Universiti Sains Malaysia, Malaysia.
Abstract
Background: Diabetes is a metabolic disorder and is a growing healthcare problem in South Asian countries. The management guidelines provided by American Diabetes Association (ADA) have provided a thorough approach for the use of oral and injectable therapies. Current statistics indicate an increase in premature mortality, which poses a severe danger to global prosperity. Sulphonylureas, biguanides, alpha glucosidase inhibitors and thiazolidinediones are examples of recent generations of drugs that have been created as a result of scientific and technological developments and have a high efficacy in reducing hyperglycemia. Objectives: This communication aims to connote the trends and availability of injectable therapy in lower middle income countries. Methodology: We reviewed a number of studies (published between 2010-2020), a market survey for availability and the Drug Regulatory Authority of Pakistan official website for the registration status of newly registered injectable therapy for managing diabetes mellitus. Results: Novel classes of drugs that have been developed as potential targets for diabetes treatment drugs include Incretin mimics, Amylin analogues, GIP analogues, Peroxisome proliferatoractivated receptors, and dipeptidyl peptidase-4 inhibitor. In Pakistan and other parts of the world, getting new insulin products in sufficient quantities has always been demanding. A list of imported insulin and GLP-1 products and their availability in lower middle income countries like Pakistan, India and Bangladesh is made so as to meet international standards. Conclusion: This short communicatiob shows the availability of Injectable therapy for management of diabetes in Pakistan.
Publication Details
Page(s) 137-148
Published Journal: International Journal of Pharmacy & Integrated Health Sciences, Volume: 4, Issue: 1, Year: 2023

Request the full text from PASTIC

Keywords
Diabetes mellitus, Diabetes mellitus, Insulin, Injectable therapy, Treatment accessibility, Lower middle-income country
0

Citations

0

Downloads

54

Views